Guided Therapeutics Expands Global Reach with New Orders
PEACHTREE CORNERS, Ga. -- Guided Therapeutics, Inc. (OTCQB: GTHP), known for its innovative LuViva Advanced Cervical Scan, has recently received an important order along with full payment from its distribution partner in Indonesia. This order includes four LuViva devices and 1,200 single-use cervical guides designed to enhance cervical cancer detection in the region.
Impactful Contribution to Indonesian Healthcare
The delivery of these advanced devices is anticipated to occur within the first quarter of 2025. This initial shipment aims to support the government healthcare system in Sulawesi, where the LuViva systems will play a crucial role in identifying women with cervical cancer at its earliest stages, thereby improving treatment outcomes significantly.
Addressing a Critical Health Issue
Sulawesi, an island within the Indonesian archipelago, boasts a population exceeding 20 million. Cervical cancer represents one of the most prevalent cancers among women in Indonesia, a country grappling with a sparse organization of screening programs, particularly in rural areas. This situation emphasizes the importance of deploying the LuViva technology in the region.
Government Support and Future Opportunities
Mark Faupel, the CEO of Guided Therapeutics, has expressed confidence in the product's capabilities. He noted, “Because LuViva is a self-contained cervical cancer detection system that provides immediate results without the need for any laboratory infrastructure, it is well suited for the Indonesian healthcare system.” This adaptability is expected to foster the growth of future orders as demand for effective cancer screening solutions increases.
About LuViva Technology
Guided Therapeutics has developed a rapid and painless testing platform that leverages patented biophotonic technology to detect diseases at the cellular level. The LuViva Advanced Cervical Scan is the company’s flagship product, allowing for non-invasive, on-the-spot detection of cervical disease. Remarkably, clinical trials indicate that this technology can identify cervical cancer up to two years earlier than traditional screening methods.
Looking Ahead
The anticipation of additional orders in the coming year suggests that demand for the LuViva system is set to grow. Guided Therapeutics is poised to expand its influence in cervical cancer detection, potentially changing the landscape of women’s health in Indonesia and beyond.
Commitment to Safety and Innovation
As Guided Therapeutics continues to innovate, it remains committed to ensuring safe use of its investigational devices. The LuViva system is currently restricted under federal law to investigational use in the U.S., highlighting the need for continued development and potential regulatory approval to maximize its impact.
Frequently Asked Questions
What is the LuViva Advanced Cervical Scan?
The LuViva Advanced Cervical Scan is a non-invasive medical device developed by Guided Therapeutics for early detection of cervical diseases.
How does LuViva benefit healthcare systems?
The device offers immediate results, requiring no laboratory setup, making it ideal for regions with limited healthcare infrastructure.
Where will the LuViva devices be deployed?
The initial shipment of LuViva devices is intended for the government healthcare system in Sulawesi, Indonesia.
What does the future hold for Guided Therapeutics?
Guided Therapeutics is expecting to secure additional orders in the near future as awareness and demand for cervical cancer screening solutions grow.
In what way is the LuViva system better than traditional methods?
The technology can detect cervical cancer much earlier than conventional screening, thus significantly improving patient outcomes.
